Premium
Recent increase in detection of alprazolam in Victorian heroin‐related deaths
Author(s) -
Rintoul Angela C,
Dobbin Malcolm D H,
Nielsen Suzanne,
Degenhardt Louisa,
Drummer Olaf H
Publication year - 2013
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/mja12.10986
Subject(s) - alprazolam , heroin , medicine , population , medical prescription , emergency medicine , pharmacology , psychiatry , drug , anxiety , environmental health
Objectives: To examine the rate of detection of alprazolam among cases of heroin‐related death (HRD) in Victoria, including the relationship between alprazolam supply and HRDs. Design and setting: Population‐based study of community alprazolam supply in Victoria and HRDs reported to the Victorian coroner from January 1990 to December 2010. Main outcome measures: Number of prescriptions for alprazolam supplied; defined daily dose (DDD) per 1000 population per day of alprazolam; number of cases of HRD in which alprazolam was detected through postmortem toxicological testing. Results: Alprazolam supply increased by 1426%, from 0.42 DDD/1000/day in 1990, to 6.41 in 2010. For every 1 unit increase in DDD/1000/day, the proportion of cases of HRD in which alprazolam was detected increased at an incidence rate ratio of 2.4 (95% CI, 2.1–2.8; P < 0.001). Alprazolam was detected among increasing proportions of HRDs, from 5.3% in 2005 to a peak of 35.3% in 2009. Conclusion: The increase in detection of alprazolam among cases of HRD, particularly since 2005, and the disproportionate increase in prescribing of the high‐dose 2 mg formulation compared with other formulations suggest a need to examine alprazolam prescribing and to identify inappropriate prescribing and the circumstances of diversion from licit to illicit use.